Hims & Hers Health Is Building A Hormonal Empire [Seeking Alpha]
Hims & Hers Health, Inc. Class A (HIMS)
Company Research
Source: Seeking Alpha
HIMS's core business growth is slowing, yet margin expansion, product innovation, and international expansion underpin mid-term shareholder value. GLP-1's legal clarity and new hormone care verticals—testosterone and menopause—offer strong upsell potential and improved retention. Valuation is attractive at a P/Gross Profit of 4.59, with upside from mean reversion and ambitious 2030 growth targets. Trevor Williams/DigitalVision via Getty Images Introduction Since my last rating , Hims & Hers Health Inc. ( HIMS ) shares are down 30% while the market is up 5%. Not a great result. Fundamentally, not much has changed. In my view: 1. The This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of HIMS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship w
Show less
Read more
Impact Snapshot
Event Time:
HIMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HIMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HIMS alerts
High impacting Hims & Hers Health, Inc. Class A news events
Weekly update
A roundup of the hottest topics
HIMS
News
- Hims & Hers And HIMZ: Short-Term Pain From Novo, Long-Term Opportunity Still Bright [Seeking Alpha]Seeking Alpha
- BofA Maintains an Underperform Rating on Hims & Hers Health, Inc. (HIMS) [Yahoo! Finance]Yahoo! Finance
- Hims & Hers: Growth Catalysts Or Margin Trap [Seeking Alpha]Seeking Alpha
- Why Hims & Hers Health (HIMS) Is Down 6.8% After Amazon Pharmacy Adds Wegovy Weight-Loss Pill [Yahoo! Finance]Yahoo! Finance
- Hims & Hers Health (NYSE:HIMS) is now covered by analysts at Evercore ISI. They set an "in-line" rating and a $33.00 price target on the stock.MarketBeat
HIMS
Earnings
- 11/3/25 - Miss
HIMS
Sec Filings
- 1/7/26 - Form 4
- 12/23/25 - Form 4
- 12/22/25 - Form 144
- HIMS's page on the SEC website